{'fraction_non_alphanumeric': 0.04353393085787452, 'fraction_numerical': 0.02560819462227913, 'mean_word_length': 4.248322147651007, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Secondary amyloidosis in rheumatoid arthritis. A clinical study of 29 patients].

BACKGROUND
To study the clinical features, outcome and response to therapy in 29 cases of rheumatoid arthritis (RA) with secondary amyloidosis (AA).


PATIENTS AND METHOD
Twenty-nine patients with RA and AA who were diagnosed during 11 years.


RESULTS
The mean age and the mean duration of RA were 63 +/- 12 years and 15 +/- 7 years respectively. The most common initial clinical feature was renal involvement (83%). Nineteen patients were treated with methotrexate. The mean survival time was 42 +/- 8 months. Eleven patients (38%) have deceased.


CONCLUSION
Our data confirms that AA in RA is a serious complication with a bleak prognosis. A normal renal function is a good prognosis indicator.